Opus Genetics (IRD) Invested Capital (2021 - 2024)
Opus Genetics (IRD) has disclosed Invested Capital for 8 consecutive years, with $50.4 million as the latest value for Q3 2023.
- On a quarterly basis, Invested Capital rose 324.14% to $50.4 million in Q3 2023 year-over-year; TTM through Sep 2023 was $50.4 million, a 324.14% increase, with the full-year FY2022 number at $46.2 million, up 108.08% from a year prior.
- Invested Capital was $50.4 million for Q3 2023 at Opus Genetics, up from $37.7 million in the prior quarter.
- In the past five years, Invested Capital ranged from a high of $50.4 million in Q3 2023 to a low of $9.8 million in Q1 2021.
- A 3-year average of $26.8 million and a median of $22.2 million in 2021 define the central range for Invested Capital.
- Peak YoY movement for Invested Capital: crashed 42.25% in 2022, then surged 324.14% in 2023.
- Opus Genetics' Invested Capital stood at $22.2 million in 2021, then surged by 108.08% to $46.2 million in 2022, then grew by 8.94% to $50.4 million in 2023.
- Per Business Quant, the three most recent readings for IRD's Invested Capital are $50.4 million (Q3 2023), $37.7 million (Q2 2023), and $41.2 million (Q1 2023).